Aurinia Pharmaceuticals Inc AUPH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AUPH is a good fit for your portfolio.
News
-
Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan
-
Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023
-
Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis
-
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
-
Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis
-
CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023
-
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)
-
Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital
Trading Information
- Previous Close Price
- $8.69
- Day Range
- $8.54–8.99
- 52-Week Range
- $4.07–12.43
- Bid/Ask
- $8.63 / $8.77
- Market Cap
- $1.24 Bil
- Volume/Avg
- 10,443 / 1.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.73
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 300
- Website
- https://www.auriniapharma.com
Valuation
|
Metric
|
AUPH
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.15 |
Price/Sales | 7.73 |
Price/Cash Flow | — |
Price/Earnings
AUPH
Financial Strength
|
Metric
|
AUPH
|
|---|---|
Quick Ratio | 5.09 |
Current Ratio | 5.77 |
Interest Coverage | — |
Quick Ratio
AUPH
Profitability
|
Metric
|
AUPH
|
|---|---|
Return on Assets (Normalized) | −9.11% |
Return on Equity (Normalized) | −11.43% |
Return on Invested Capital (Normalized) | −12.61% |
Return on Assets
AUPH
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ylvcd | $453.9 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ljbkfvm | $90.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wgjzwg | $88.1 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Gvbxjb | $40.3 Bil | |
MRNA
| Moderna Inc | Slwxs | $30.1 Bil | |
ARGX
| argenx SE ADR | Dvrdj | $26.1 Bil | |
BNTX
| BioNTech SE ADR | Wcv | $23.6 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Kqjmxd | $20.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fwltqbr | $16.9 Bil | |
INCY
| Incyte Corp | Qszvkb | $12.0 Bil |